Artivion Inc (AORT) FinancialsAORTFinancialArtivion Inc

Artivion Inc (AORT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Aortic stent grafts, accounting for 38.2% of total sales, equivalent to $44.40M. Other significant revenue streams include On X and Preservation Services. Understanding this composition is critical for investors evaluating how AORT navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Artivion Inc maintains a gross margin of 64.03%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -0.29%, while the net margin is -10.74%. These profitability ratios, combined with a Return on Equity (ROE) of -0.73%, provide a clear picture of how effectively AORT converts its operational activities into shareholder value.

In the context of the broader market, AORT competes directly with industry leaders such as IART and DRTS. With a market capitalization of $1.42B, it holds a significant position in the sector. When comparing efficiency, AORT's gross margin of 64.03% stands against IART's 54.90% and DRTS's N/A. Such benchmarking helps identify whether Artivion Inc is trading at a premium or discount relative to its financial performance.

Artivion's total revenue has shown a positive trend, increasing from $95.77 million in Q3 2024 to $125.76 million in Q2 2026. However, net income has fluctuated with significant losses reported in recent quarters, including a $13.49 million loss in Q2 2026.